Adimab and Biogen Idec have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Biogen Idec. The agreement gives Biogen Idec the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.
Adimab and Lilly have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Lilly. For each target, the agreement grants Lilly the right to research antibodies generated from the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive various upfront fees including research fees and technical milestones. In addition, for each target, Lilly will have the sole option to exclusively license antibodies from the collaboration, and if Lilly were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.
Adimab and Roche have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against a target selected by Roche. The agreement allows Roche the right to commercialize antibodies generated from the collaboration as therapeutic and diagnostic products. Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive milestones and royalties on therapeutic and diagnostic product sales.
- Roche confirmed the successful delivery of several hundred IgGs within 8 weeks of starting an antibody discovery program with Adimab. The IgGs delivered met specific criteria as outlined in the contract.
> Roche
Adimab and Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against two targets selected by Genentech. Under the terms of the agreement, Genentech has rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.
Adimab and Human Genome Sciences, of Rockville MD, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one target selected by Human Genome Sciences. The agreement gives Human Genome Sciences the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.
Adimab and Merck have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against targets selected by Merck. The agreement grants Merck the right to commercialize antibodies generated from the collaboration as therapeutic products. Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive milestones and royalties on therapeutic product sales.
- Merck confirmed delivery of a panel of antibodies that met criteria outlined in the original agreement within 8 weeks of the initiation of the discovery program.
- Adimab has also announced the achievement of a second milestone from its ongoing collaboration with Merck.
Adimab and Merrimack Pharmaceuticals, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against targets selected by Merrimack Pharmaceuticals. The agreement gives the Merrimack Pharmaceuticals rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones, commercial milestones and royalties on therapeutic and diagnostic product sales.
Adimab and Novartis have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novartis. The agreement grants Novartis the right to commercialize antibodies generated from the collaboration as therapeutic and diagnostic products. Under the terms of the agreements, Adimab will receive a combination of upfront payments, license fees, clinical milestones, and royalties on therapeutic and diagnostic product sales.
> Novartis
Adimab and Novo Nordisk have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novo Nordisk. The agreement gives Novo Nordisk the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.
Adimab and Pfizer have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against a Central Nervous System/Pain target selected by Pfizer. The agreement grants Pfizer the right to commercialize antibodies generated from the collaboration as therapeutic products. Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive milestones and royalties on therapeutic and diagnostic product sales.
> Pfizer